Opinion
Video
Author(s):
Experts on prostate cancer discuss how treatment has evolved over the years, focusing on doublet and triplet therapy and their utility.
Darolutamide is safe, efficacious in mHSPC regardless of patient age
Dr. Murphy on increasing diversity in cancer clinical trials
STOPCAP: ARPIs benefit younger patients with mHSPC
Dr. Schwen on focal therapies for prostate cancer
FDA grants 510(k) clearance to AI-powered prostate cancer diagnostic
Biomarkers in advanced prostate cancer: Liquid biopsy, ctDNA, and more